Your browser is no longer supported. Please, upgrade your browser.
ASLN ASLAN Pharmaceuticals Limited weekly Stock Chart
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-1.24 Insider Own- Shs Outstand37.99M Perf Week1.85%
Market Cap62.69M Forward P/E- EPS next Y-0.50 Insider Trans- Shs Float36.90M Perf Month-5.71%
Income- PEG- EPS next Q-0.07 Inst Own8.68% Short Float0.04% Perf Quarter6.45%
Sales- P/S- EPS this Y72.40% Inst Trans- Short Ratio0.14 Perf Half Y-23.26%
Book/sh-0.23 P/B- EPS next Y-25.00% ROA- Target Price- Perf Year-39.56%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.35 - 8.18 Perf YTD-18.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.83% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low371.43% ATR0.12
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)43.83 Volatility4.80% 6.78%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.32 Prev Close1.66
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume105.95K Price1.65
Recom2.30 SMA20-3.93% SMA50-9.95% SMA200-8.74% Volume34,494 Change-0.60%
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Aug-07-20 03:00AM  
Jul-17-20 06:08AM  
Jul-13-20 12:00PM  
Jun-25-20 08:50AM  
Jun-19-20 05:50PM  
Jun-11-20 12:00PM  
Jun-04-20 09:46PM  
May-11-20 05:34AM  
May-07-20 05:50PM  
Apr-20-20 08:56AM  
Apr-13-20 04:21AM  
Mar-26-20 12:00PM  
Mar-18-20 05:18AM  
Feb-24-20 02:05AM  
Feb-20-20 05:50PM  
Feb-10-20 05:45PM  
Feb-04-20 05:45PM  
Jan-28-20 10:39AM  
Jan-27-20 11:30AM  
Jan-15-20 04:34PM  
Jan-14-20 08:53AM  
Jan-13-20 12:00PM  
Jan-06-20 12:04PM  
Dec-18-19 09:58AM  
Dec-05-19 06:22PM  
Dec-03-19 02:29PM  
Dec-02-19 01:34PM  
Nov-22-19 08:18AM  
Nov-11-19 12:36PM  
Nov-08-19 09:00AM  
Nov-06-19 11:00AM  
Oct-31-19 03:37AM  
Oct-22-19 02:45AM  
Oct-18-19 03:35AM  
Oct-02-19 02:30AM  
Sep-30-19 02:35AM  
Sep-19-19 03:50AM  
Sep-10-19 05:14AM  
Aug-27-19 06:00AM  
Aug-13-19 04:03AM  
Jul-31-19 04:14AM  
Jul-26-19 04:20AM  
Jul-01-19 09:00AM  
Jun-04-19 08:00AM  
May-31-19 03:15AM  
May-10-19 04:15AM  
May-06-19 09:00AM  
Apr-29-19 05:02AM  
Mar-29-19 12:13PM  
Mar-28-19 10:41AM  
Mar-22-19 07:25AM  
Mar-11-19 03:00AM  
Feb-26-19 05:35PM  
Jan-29-19 05:40PM  
Jan-23-19 01:35AM  
Jan-14-19 06:34PM  
Jan-13-19 05:30PM  
Jan-04-19 02:00AM  
Jan-02-19 03:48AM  
Dec-02-18 12:00PM  
Nov-27-18 04:47AM  
Nov-20-18 05:00AM  
Nov-08-18 06:05AM  
Nov-01-18 10:20AM  
Oct-30-18 03:54AM  
Oct-22-18 07:00AM  
Oct-17-18 12:31PM  
Oct-09-18 06:15AM  
Sep-21-18 04:00AM  
Sep-17-18 06:58AM  
Sep-04-18 02:47AM  
Aug-20-18 02:49AM  
Aug-10-18 08:19AM  
Aug-06-18 04:05AM  
Jul-03-18 04:01AM  
May-30-18 01:47PM  
May-17-18 02:25AM  
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.